Category Archives: Other

Lilly Doubles Down on LillyDirect Program; Tandem AID Algorithm Cleared for T2DM; Compounders Sue FDA… Again; Lilly Acquires FXR Program; Terns Development Updates

A series of cardiometabolic-related news items have been observed from Lilly, Tandem Diabetes Care, the Outsourcing Facilities Association, Lilly/Organovo, and Terns Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items. 

This content is for Read Less members only.
Already a member? Log in here

Lilly Stockpiles Orfoglipron; February CHMP Agenda Observed

Two cardiometabolic-related news items have been observed: Lilly has stockpiled $548M worth of orforglipron in a risky move ahead of the regulatory filing/approval (view 10-K); and the CHMP agenda (view here) for this month’s meeting (Feb 24-27) has been released. Below, FEINX provides highlights and insights for the respective news items.  

This content is for Read Less members only.
Already a member? Log in here

Coming Soon: FENIX Obesity Spotlight Series

With the obesity market hot, FENIX is conducting a spotlight series throughout H1 2025 by deep diving into competitors’ portfolio approaches. The series will look to uncover key strategies that will shape the obesity market over the next 5-10 years from companies such as: Novo Nordisk, Lilly, AstraZeneca, Amgen, Boehringer Ingelheim, Roche, Merck, Regeneron, Pfizer, and others.

This content is for Read Less members only.
Already a member? Log in here

Dexcom Q4 ’24 Earnings

Dexcom hosted its Q4 ‘24 earnings call (press release; slides) and provided updates across its business. Importantly, the company provided additional details into its next-gen G8 sensor platform. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Already a member? Log in here